Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19 - Archive ouverte HAL Access content directly
Journal Articles Clinical Infectious Diseases Year : 2021

Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19

(1, 2) , (1, 2) , (3, 4, 5) , (1, 2) , (3) , (6) , (3) , (7) , (8) , (9) , (2) , (10, 11) , (11, 12) , (13) , (8) , (3, 4, 5) , (8, 12) , (1, 2) ,
1
2
3
4
5
6
7
8
9
10
11
12
13
Blandine Monel
Timothée Bruel
Anne Blanchard
Hélène Péré

Abstract

Background: Humoral response to SARS-CoV-2 occurs within the first weeks after COVID-19. Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution overtime after COVID-19 as well as efficiency against novel variants are however poorly characterized. Methods: In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3- and 6-months post-infection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-Spike (S) and anti-Nucleocapsid (NP) IgG. Findings: Levels of sero-neutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with sero-neutralization and this correlation was stronger for anti-S than for anti-NP antibodies. The level of sero-neutralization quantified at 6 months correlated with markers of initial severity, notably admission in intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against D614G, B.1.1.7 and P.1 variants but a significantly weaker activity against B.1.351 variant. Interpretation: Decrease of IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.
Fichier principal
Vignette du fichier
ciab308.pdf (1.4 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

pasteur-03229817 , version 1 (19-05-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Maureen Betton, Marine Livrozet, Delphine Planas, Antoine Fayol, Blandine Monel, et al.. Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19. Clinical Infectious Diseases, 2021, pp.ciab308. ⟨10.1093/cid/ciab308⟩. ⟨pasteur-03229817⟩
65 View
48 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More